Breast prostheses are implanted for augmentation or during reconstructive surgery. One of the more commonly used prostheses is the polyurethane-sponge-covered silicone gel implant. Some clinicians are concerned about the safety of this product because the polyurethane foam disintegrates in vivo, and its subsequent fate is not known.
no one knows exactly what happens to the polyurethane sponge and whether the breakdown products from the sponge have any adverse effects on the body.
Polyurethane is a polymer formed by reacting polyols and diisocyanates. The reactant most commonly used is toluenediisocyanate (TDI).3 TDI is a reactive compound and is converted into toluenediamine (TDA) on contact with water. TDI is a known irritant to the eyes, upper respiratory tract, and skin (4), and TDA has been shown to be a mutagen and to produce liver cancers in rats (5) . Although the foam coating is known to disintegrate in the body, not much is known about its fate. However, if polyurethane breaks down into its monomers, then TDA would be expected to show up in the body. Indeed, we report here the presence of TDA in body fluids from a patient who has polyurethane-covered implants.
Case History
A 41-year-old woman underwent aesthetic breast augmentation in October 1988. Silicone gel implants were placed below the pectoral muscles. Despite this submuscular position, results were undesirable because of encapsulation of the left implant and lateral displacement of the right implant. In November 1989, these submuscular, smooth-walled implants were removed and a polyurethane-sponge-covered implant (Meme#{174}; Surgitek, Rncine, WI 53404) was placed in a new pocket created between the breast and the pectoral muscles on each side. Over the next several weeks, the implant on the left gradually became encapsulated and firm, and this side appeared to grow larger. On June 1, 1990, the left breast was re-explored and the implant was found to be encapsulated. The capsule was entered, and the gel implant was easily extracted. The surface of this gel implant was rough, indicating that the gel wall either had been designed to be rough or was coated with an adhesive. The polyurethane cover appeared partially absorbed, and it was enmeshed in, or integrated with, the scar encapsulating the implant. This scar was completely removed, revealing that the apparent enlargement of the left side was the result of a collection of fluid in the submuscular pocket where the previous implant had been placed. The submuscular smooth-walled scar was drained and partially excised. A new Meme implant was inserted. The entire encapsulating scar tissue was submitted for analysis. Also submitted was a urine specimen obtained during operation. We also analyzed several urine specimens from the same patient that were collected two to three weeks after the operation.
Materials and Methods

Sample Preparation
In this set of experiments, we looked for free diaxnines in the biological specimen, as well as diamines generated after acid hydrolysis. When exposed to methylenediphenyldiamine (MDA), subjects excrete acetylated diamine in urine (6) . The acetylated diamines can be deconjugated by acid hydrolysis (7) . Dianunes are also produced by subjecting polyurethane foam to acid hydrolysis.
To detect free dianiines in the scar tissue, we weighed the excised scar tissue and soaked 0.306 g of it in 2 mL of distilled water for 3 h at room temperature before analyzing the aqueous portion. To detect bound diamines in the scar tissue, we boiled 0.225 g of the tissue in 1 mL of 6 mol/L hydrochloric acid for 1 h. An aliquot was then diluted 1000-fold with distilled water to 2 mL and analyzed.
To detect bound diamines in the urine, we mixed 2 mL of urine with 1 mL of 6 molIL hydrochloric acid, boiled the mixture for 1 h, then analyzed the entire sample.
Analysis
We used the analytical methods of Rosenberg and Savolainen (7) , with some modifications. After alkalinizing the biological fluid with sodium hydroxide, we extracted the dianiine from the aqueous layer into toluene. Heptafluorobutyric anhydride was added to the organic fraction to derivatize the diamine at room temperature into its heptafluorobutyryl (HFB) analog. We then analyzed the derivative by gas chromatographymass spectrometry.
Details of these procedures will be published.
Because there are two possible monomers of polyurethane foam, TDI and methylenediphenyldiisocyanate, we screened the biological fluids for the corresponding diamines TDA and MDA, using selected ion monitoring. Once the monomer was identified as TDI, we quantified TDA by comparing the m/z 345 ion intensity in the patient's specimens with those from a set of TDA calibrators, with 1,6-hexanediamine (mlz = 226) used as an internal standard.
Results and DIscussion
The two isomeric forms of TDI in commercial preparations, 2,4-TDI and 2,6-TDI, exist in the ratio 4:1. Their corresponding reaction products with water are 2,4-TDA and 2,6-TDA. Both forms of diamines were found in the hydrolyzed scar tissue. The mass spectra of 2,4-TDA-HFB from the scar tissue and that from the authentic substance are shown in Figure 1 . Clearly, the two mass spectra are identical. Figure 2 shows the molecular structure of 2,4-TDA-HFB, along with the interpretation of the ions used to monitor the compound. The retention time (6.6 mm) of 2,4-TDA-HFB from the scar tissue hydrolysate also agrees with that of the authentic substance. Similar data were obtained for 2,6-TDA-HFB.
Thus, we conclude that the monomers in the polyurethane foam are 2,4-TDI and 2,6-TDI.
Because we found no free diamines in the scar tissue (Table 1) , the diamines detected must originate from other compounds that are hydrolyzable by acid. The concentrations of the TDAs in the scar tissue were very high, more than 10000-fold those in the urine. The most likely source of these dianiines is the polyurethane foam fragments that are incorporated into the scar tissue. Figure 3 compares the ion chromatograms of 2,4-
TDA-HFB
in a urine specimen from the patient with those of a calibration standard. The retention times and the ion ratios of the compounds from the two sources agree well. The peak area of the m/z 345 ion, the base ion, is used for calculation of TDA concentration. Table  1 lists the TDA contents detected in various biological samples. Urine specimens collected from the patient on the day of the operation, and on several dates afterward, all contain both 2,4-TDA and 2,6-TDA. The concentrations are quite consistent, about 1 g/L, and vary directly with the creatimne concentration of the urine. The concentration of 2,4-TDA is greater than that of 2,6-TDA, in agreement with the fact that commercial preparations of TDI are a mixture of the two isomers, with 2,4-TDI at a higher concentration.
Three other urine specimens from patients with breast implants
were submitted for analysis and were all negative for TDA. We later learned that the implants used by these patients were not coated with polyurethane foam. Urine specimens from six female staff members were analyzed as controls, and were also 
